Nasal Drug Delivery Market Research Report - Global Forecast till 2030

Global Nasal Drug Delivery Market Research Report: Information by Drug Type (Anesthetics, Antibiotics), Dosage Form (Drops, Sprays), Basis of System (Unit Dose, Multi-Dose), Delivery Technologies (Spray, Nebulizers), Therapeutic Applications (Rhinitis, Asthma) End User (Home Care Settings) and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2030

ID: MRFR/Pharma/2003-HCR | August 2022 | Region: Global | 84 Pages         


TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Overview

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

Chapter 6. Global Nasal Drug Delivery Market, by Drug Type

6.1 Overview

6.2 Anesthetics

6.3 Antibiotics

6.4 Pain Relief Drugs

6.5 Calcium Supplements

6.6 Vasoconstrictors

6.7 Antihistamines

6.8 Others

Chapter 7. Global Nasal Drug Delivery Market, by Dosage Form

7.1 Overview

7.2 Drops

7.3 Sprays

7.4 Powder

7.5 Gels and Ointments

Chapter 8. Global Nasal Drug Delivery Market, by Basis of System

8.1 Overview

8.2 Unit Dose

8.3 Multi-Dose

8.4 Metered Dose

Chapter 9. Global Nasal Drug Delivery Market, by Delivery Technologies

9.1 Overview

9.2 Spray

9.3 Nebulizers

9.4 Inhalers

9.5 Others

Chapter 10. Global Nasal Drug Delivery Market, by Therapeutic Applications

10.1 Overview

10.2 Rhinitis

10.3 Asthma

10.4 Nasal Congestion

10.5 Chronic Obstructive Pulmonary Disease (COPD)

10.6 Cystic Fibrosis

10.7 Others

Chapter 11. Global Nasal Drug Delivery Market, by End Users

11.1 Overview

11.2 Home Care Settings

11.3 Hospitals & Clinics

Chapter 12. Global Nasal Drug Delivery Market, by Region

12.1 Overview

12.2 America

12.2.1 North America

12.2.1.1 US

12.2.1.2 Canada

12.2.2 Latin America

12.3 Europe

12.3.1 Western Europe

12.3.1.1 Germany

12.3.1.2 France

12.3.1.3 Italy

12.3.1.4 Spain

12.3.1.5 UK

12.3.1.6 Rest of Western Europe

12.3.2 Eastern Europe

12.4 Asia-Pacific

12.4.1 Japan

12.4.2 China

12.4.3 India

12.4.4 Australia

12.4.5 South Korea

12.4.6 Rest of Asia-Pacific

12.5 Middle East & Africa

12.5.1 Middle East

12.5.2 Africa

Chapter 13. Company Landscape

13.1 Overview

13.2 Market Share Analysis

13.3 Key Development & Strategies

13.3.1 Key Developments

Chapter 14 Company Profiles

14.1 GlaxoSmithKline Plc.

14.1.1 Company Overview

14.1.2 Type Overview

14.1.3 Financials

14.2.4 Key Developments

14.1.5 SWOT Analysis

14.2 AstraZeneca

14.2.1 Company Overview

14.2.2 Type Overview

14.2.3 Financial Overview

14.2.4 Key Developments

14.2.5 SWOT Analysis

14.3 Pfizer, Inc.

14.3.1 Company Overview

14.3.2 Type Overview

14.3.3 Financial Overview

14.3.4 Key Development

14.3.5 SWOT Analysis

14.4 Becton Dickson & Company

14.4.1 Company Overview

14.4.2 Type/Business Segment Overview

14.4.3 Financial Overview

14.4.4 Key Development

14.4.5 SWOT Analysis

14.5 Promius Pharma

14.5.1 Company Overview

14.5.2 Type Overview

14.5.3 Financial overview

14.5.4 Key Developments

14.5.5 SWOT Analysis

14.6 Sanofi-Aventis

14.6.1 Company Overview

14.6.2 Type Overview

14.6.3 Financial Overview

14.6.4 Key Developments

14.6.5 SWOT Analysis

14.7 Merck & Co.

14.7.1 Overview

14.7.2 Type Overview

14.7.3 Financials

14.7.4 Key Developments

14.7.5 SWOT Analysis

14.8 Cadila Pharmaceuticals

14.8.1 Overview

14.8.2 Type Overview

14.8.3 Financials

14.8.4 Key Developments

14.8.5 SWOT Analysis

14.9 AEGIS THERAPEUTICS LLC

14.9.1 Overview

14.9.2 Type Overview

14.9.3 Financials

14.9.4 Key Developments

14.9.5 SWOT Analysis

14.14 Novartis AG

14.14.1 Overview

14.14.2 Type Overview

14.14.3 Financials

14.14.4 Key Developments

14.14.5 SWOT Analysis

14.11 Johnson & Johnson Services, Inc.

14.11.1 Overview

14.11.2 Type Overview

14.11.3 Financials

14.11.4 Key Developments

14.11.5 SWOT Analysis

14.12 3M COMPANY

14.12.1 Overview

14.12.2 Type Overview

14.12.3 Financials

14.12.4 Key Developments

14.12.5 SWOT Analysis

14.13 Others

Chapter 15 Appendix

LIST OF TABLES

Table 1 Global Nasal Drug Delivery Market Industry Synopsis, 2020-2027

Table 2 Global Nasal Drug Delivery Market Estimates & Forecast, 2020-2027, (USD Million)

Table 3 Global Nasal Drug Delivery Market, by Region, 2020-2027, (USD Million)

Table 4 Global Nasal Drug Delivery Market, by Drug Type, 2020-2027, (USD Million)

Table 5 Global Nasal Drug Delivery Market, by Dosage Form, 2020-2027, (USD Million)

Table 6 Global Nasal Drug Delivery Market, by Basis of System, 2020-2027, (USD Million)

Table 7 Global Nasal Drug Delivery Market, by Delivery Technologies, 2020-2027, (USD Million)

Table 8 Global Nasal Drug Delivery Market, by Therapeutic Applications, 2020-2027, (USD Million)

Table 9 Global Nasal Drug Delivery Market, by End Users, 2020-2027, (USD Million)

Table 10 North America: Nasal Drug Delivery Market, by Drug Type, 2020-2027, (USD Million)

Table 11 North America: Nasal Drug Delivery Market, by Dosage Form, 2020-2027, (USD Million)

Table 12 North America: Nasal Drug Delivery Market, by Basis of System, 2020-2027, (USD Million)

Table 13 North America: Nasal Drug Delivery Market, by Delivery Technologies, 2020-2027, (USD Million)

Table 14 North America: Nasal Drug Delivery Market, by Therapeutic Applications, 2020-2027, (USD Million)

Table 15 North America: Nasal Drug Delivery Market, by End Users, 2020-2027, (USD Million)

Table 16 US: Nasal Drug Delivery Market, by Drug Type, 2020-2027, (USD Million)

Table 17 US: Nasal Drug Delivery Market, by Dosage Form, 2020-2027, (USD Million)

Table 18 US: Nasal Drug Delivery Market, by Basis of System, 2020-2027, (USD Million)

Table 19 US: Nasal Drug Delivery Market, by Delivery Technologies, 2020-2027, (USD Million)

Table 20 US: Nasal Drug Delivery Market, by Therapeutic Applications, 2020-2027, (USD Million)

Table 21 US: Nasal Drug Delivery Market, by End Users, 2020-2027, (USD Million)

Table 22 Canada: Nasal Drug Delivery Market, by Drug Type, 2020-2027, (USD Million)

Table 23 Canada: Nasal Drug Delivery Market, by Dosage Form, 2020-2027, (USD Million)

Table 24 Canada: Nasal Drug Delivery Market, by Basis of System, 2020-2027, (USD Million)

Table 25 Canada: Nasal Drug Delivery Market, by Delivery Technologies, 2020-2027, (USD Million)

Table 26 Canada: Nasal Drug Delivery Market, by Therapeutic Applications, 2020-2027, (USD Million)

Table 27 Canada: Nasal Drug Delivery Market, by End Users, 2020-2027, (USD Million)

Table 28 Latin America: Nasal Drug Delivery Market, by Drug Type, 2020-2027, (USD Million)

Table 29 Latin America: Nasal Drug Delivery Market, by Dosage Form, 2020-2027, (USD Million)

Table 30 Latin America: Nasal Drug Delivery Market, by Basis of System, 2020-2027, (USD Million)

Table 31 Latin America: Nasal Drug Delivery Market, by Delivery Technologies, 2020-2027, (USD Million)

Table 32 Latin America: Nasal Drug Delivery Market, by Therapeutic Applications, 2020-2027, (USD Million)

Table 33 Latin America: Nasal Drug Delivery Market, by End Users, 2020-2027, (USD Million)

Table 34 Europe: Nasal Drug Delivery Market, Drug Type, 2020-2027, (USD Million)

Table 35 Europe: Nasal Drug Delivery Market, by Dosage Form, 2020-2027, (USD Million)

Table 36 Europe: Nasal Drug Delivery Market, by Basis of System, 2020-2027, (USD Million)

Table 37 Europe: Nasal Drug Delivery Market, by Delivery Technologies, 2020-2027, (USD Million)

Table 38 Europe: Nasal Drug Delivery Market, by Therapeutic Applications, 2020-2027, (USD Million)

Table 39 Europe: Nasal Drug Delivery Market, by End Users, 2020-2027, (USD Million)

Table 40 Western Europe: Nasal Drug Delivery Market, by Drug Type, 2020-2027, (USD Million)

Table 41 Western Europe: Nasal Drug Delivery Market, by Dosage Form, 2020-2027, (USD Million)

Table 42 Western Europe: Nasal Drug Delivery Market, by Basis of System, 2020-2027, (USD Million)

Table 43 Western Europe: Nasal Drug Delivery Market, by Delivery Technologies, 2020-2027, (USD Million)

Table 44 Western Europe: Nasal Drug Delivery Market, by Therapeutic Applications, 2020-2027, (USD Million)

Table 45 Western Europe: Nasal Drug Delivery Market, by End Users, 2020-2027, (USD Million)

Table 46 Western Europe: Nasal Drug Delivery Market, by Drug Type, 2020-2027, (USD Million)

Table 47 Eastern Europe: Nasal Drug Delivery Market, by Dosage Form, 2020-2027, (USD Million)

Table 48 Eastern Europe: Nasal Drug Delivery Market, by Basis of System, 2020-2027, (USD Million)

Table 49 Eastern Europe: Nasal Drug Delivery Market, by Delivery Technologies, 2020-2027, (USD Million)

Table 50 Eastern Europe: Nasal Drug Delivery Market, by Therapeutic Applications, 2020-2027, (USD Million)

Table 51 Eastern Europe: Nasal Drug Delivery Market, by Patent Type, 2020-2027, (USD Million)

Table 52 Eastern Europe: Nasal Drug Delivery Market, by End Users, 2020-2027, (USD Million)

Table 53 Asia-Pacific: Nasal Drug Delivery Market, by Drug Type, 2020-2027, (USD Million)

Table 54 Asia-Pacific: Nasal Drug Delivery Market, by Dosage Form, 2020-2027, (USD Million)

Table 55 Asia-Pacific: Nasal Drug Delivery Market, by Basis of System, 2020-2027, (USD Million)

Table 56 Asia-Pacific: Nasal Drug Delivery Market, by Delivery Technologies, 2020-2027, (USD Million)

Table 57 Asia-Pacific: Nasal Drug Delivery Market, by Therapeutic Applications, 2020-2027, (USD Million)

Table 58 Asia-Pacific: Nasal Drug Delivery Market, by End Users, 2020-2027, (USD Million)

Table 59 Middle East & Africa: Nasal Drug Delivery Market, by Drug Type, 2020-2027, (USD Million)

Table 60 Middle East & Africa: Nasal Drug Delivery Market, by Dosage Form, 2020-2027, (USD Million)

Table 61 Middle East & Africa: Nasal Drug Delivery Market, by Basis of System, 2020-2027, (USD Million)

Table 62 Middle East & Africa: Nasal Drug Delivery Market, by Delivery Technologies, 2020-2027, (USD Million)

Table 63 Middle East & Africa: Nasal Drug Delivery Market, by Therapeutic Applications, 2020-2027, (USD Million)

Table 64 Middle East & Africa: Nasal Drug Delivery Market, by End Users, 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Application

Figure 2 Market Structure of the Global Nasal Drug Delivery Market

Figure 3 Market Dynamics of the Global Nasal Drug Delivery Market

Figure 4 Global Nasal Drug Delivery Market Share, by Drug Type 2020

Figure 5 Global Nasal Drug Delivery Market Share, by Dosage Form 2020

Figure 6 Global Nasal Drug Delivery Market Share, by Basis of System 2020

Figure 7 Global Nasal Drug Delivery Market Share, by Delivery Technologies 2020

Figure 8 Global Nasal Drug Delivery Market Share, by Therapeutic Applications 2020

Figure 9 Global Nasal Drug Delivery Market Share, by End Users, 2020

Figure 10 Global Nasal Drug Delivery Market Share, by Region, 2020

Figure 11 North America Nasal Drug Delivery Market Share, by Country, 2020

Figure 12 Europe Prescribed Health Apps Share, by Country, 2020

Figure 13 Asia-Pacific Nasal Drug Delivery Market Share, by Country, 2020

Figure 14 Middle East & Africa Nasal Drug Delivery Market Share, by Country, 2020

Figure 15 Global Nasal Drug Delivery Market: Company Share Analysis, 2020 (%)

Figure 16 GlaxoSmithKline Plc.: Key Financials

Figure 17 GlaxoSmithKline Plc.: Segmental Revenue

Figure 18 GlaxoSmithKline Plc.: Geographical Revenue

Figure 19 AstraZeneca: Key Financials

Figure 20 AstraZeneca: Segmental Revenue

Figure 21 AstraZeneca: Geographical Revenue

Figure 22 Pfizer, Inc.: Key Financials

Figure 23 Pfizer, Inc.: Segmental Revenue

Figure 24 Pfizer, Inc.: Geographical Revenue

Figure 25 Becton Dickson & Company: Key Financials

Figure 26 Becton Dickson & Company: Segmental Revenue

Figure 27 Becton Dickson & Company: Geographical Revenue

Figure 28 Promius Pharma: Key Financials

Figure 29 Promius Pharma: Segmental Revenue

Figure 30 Promius Pharma: Geographical Revenue

Figure 31 Sanofi-Aventis: Key Financials

Figure 32 Sanofi-Aventis: Segmental Revenue

Figure 33 Sanofi-Aventis: Geographical Revenue

Figure 34 Merck & Co.: Key Financials

Figure 35 Merck & Co.: Segmental Revenue

Figure 36 Merck & Co.: Geographical Revenue

Figure 37 Cadila Pharmaceuticals: Key Financials

Figure 34 Cadila Pharmaceuticals: Segmental Revenue

Figure 35 Cadila Pharmaceuticals Geographical Revenue

Figure 36 AEGIS THERAPEUTICS LLC: Key Financials

Figure 37 AEGIS THERAPEUTICS LLC: Segmental Revenue

Figure 38 AEGIS THERAPEUTICS LLC: Geographical Revenue

Figure 39 Novartis AG: Key Financials

Figure 40 Novartis AG: Segmental Revenue

Figure 41 Novartis AG: Geographical Revenue

Figure 42 Johnson & Johnson Services, Inc.: Key Financials

Figure 43 Johnson & Johnson Services, Inc.: Segmental Revenue

Figure 44 Johnson & Johnson Services, Inc.: Geographical Revenue

Nasal Drug Delivery Market

The Nasal Drug Delivery Market is touted to reach USD 52,998.5 Million at CAGR of 7.50 % by the end of 2020-2030.

Segmentation

By Drug Type Anesthetics Antibiotics
Dosage Form Drops Sprays
Basis of System Unit Dose Multi Dose
Delivery Technologies Spray Nebulizers
End User Home Care Settings

Key Players

  • GlaxoSmithKline Plc. (UK)
  • AstraZeneca (UK)
  • Pfizer
  • Inc. (US)
  • Becton Dickson & Company (US)
  • Dr. Reddy’s Laboratories Ltd. (India)
  • Sanofi-Aventis (UK)
  • Merck & Co. (US)
  • Cadila Pharmaceuticals (India)
  • AEGIS THERAPEUTICS LLC (US)
  • Novartis AG (UK)
  • Johnson & Johnson Services
  • Inc (US) and 3M COMPANY (US)

Drivers

  • Increasing number of patient population with respiratory problem
Speak to Analyst Request a Free Sample

Nasal Drug Delivery Market Overview


The nasal drug delivery market was valued at USD 52,998.5 million in 2018 and is projected to reach USD 79.4 Billion at 7.50% CAGR during the forecaast period 2022-2030.


Nasal drug delivery is administration of drug through the nasal track to treat various respiratory problems such as paranasal sinuses, nasal infection, and other nasal problems. It is an effective delivery method for medicines that are active in low doses.


Factors such as the painless drug administration, development of new technological nasal drug delivery devices, and the increasing number of patient population with respiratory problem are expected to drive the market growth. Moreover, nasal drug delivery devices are easily accessible and suitable for self-medication it has received positive response from patient population, clinicians, and pharmaceutical scientists.  


However, factors such as low bioavailability, nasal irritation, and irreversible damage of cilia of cell is expected to hamper the market growth. 


Segmentation


The global nasal drug delivery market has been segmented into drug type, dosage form, basis of system, delivery technologies, therapeutic applications, end users, and region.


Based on drug type, the global market has been segmented into anesthetics, antibiotics, pain relief drugs, calcium supplements, vasoconstrictors, antihistamines, and others.


Based on dosage form, the global market has been segmented into drops, sprays, powder, gels, and ointments.


Based on the basis of system, the global nasal drug delivery market has been segmented into unit dose, multi-dose, and metered dose.


Based on delivery technologies, the global market has been segmented into spray, nebulizers, inhalers, and others.


Based on therapeutic applications, the global market has been segmented into rhinitis, asthma, nasal congestion, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and others.


The global market, by end user, has been divided into home care settings and hospitals & clinics.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The nasal drug delivery market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.


The European nasal drug delivery market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The Asia-Pacific nasal drug delivery market has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.


The nasal drug delivery market in the Middle East & Africa has been segmented into the Middle East and Africa. The increasing development in healthcare infrastructure and growing economy in countries such as Kuwait, Iran, Israel, and Iraq drive the market growth in this region.  


Key Players


GlaxoSmithKline Plc. (UK), AstraZeneca (UK), Pfizer, Inc. (US), Becton Dickson & Company (US), Dr. Reddy’s Laboratories Ltd. (India), Sanofi-Aventis (UK), Merck & Co. (US), Cadila Pharmaceuticals (India), AEGIS THERAPEUTICS LLC (US), Novartis AG (UK) , Johnson & Johnson Services, Inc (US) and 3M COMPANY (US) are some of the key players in the global nasal drug delivery market.


Regional Market Summary


Geographically, the market has been segmented, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the global nasal drug delivery market owing to an increasing prevalence of rhinitis, congestion, sinusitis, and respiratory allergic reactions.


Additionally, the well-developed healthcare sector and presence of a large number of medical device companies in this region boosts the market growth. According to the Centers for Disease Control and Prevention January 2017, 30.8 million adults were diagnosed with sinusitis in the US.


Europe is expected to hold the second-largest position in the global nasal drug delivery market. The presence of a large patient population suffering from chronic disorders, increasing technological advancement in the healthcare industry, and growing mergers and acquisitions between healthcare companies drives the market growth in this region.


Alabama Nasal Drug Delivery Association (ADMEA) is a Europe based non-profit organization involved in providing home medical equipment. The presence of such organization in Europe enhances the market growth during the forecasted period.


Asia-Pacific is expected to be fastest-growing region owing to the growing geriatric population and increasing incidences of allergy diseases, which is a common cause of respiratory problems in developing countries.


The Middle East & Africa holds the least share of the market. A majority of the market share of this region is expected to be held by the Middle East due to growing government initiatives for the healthcare sector in this region.
By Drug Type



  • Anesthetics

  • Antibiotics

  • Pain Relief Drugs

  • Calcium Supplements

  • Vasoconstrictors

  • Antihistamines

  • Others


By Dosage Form



  • Drops

  • Sprays

  • Powder

  • Gels and Ointments


By Basis of System



  • Unit Dose

  • Multi-Dose

  • Metered Dose


By Delivery Technologies



  • Spray

  • Nebulizers

  • Inhalers

  • Others


By Application



  • Rhinitis

  • Asthma

  • Nasal Congestion

  • Chronic Obstructive Pulmonary Disease (COPD)

  • Cystic Fibrosis

  • Others


By End User



  • Hospital/Clinic

  • Ambulatory Surgical Center

  • Research Centers

  • Home Healthcare

  • Others


By Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America



  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe



  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • Middle East & Africa

    • Middle East

    • Africa




Intended Audience



  • Medical device manufacturing companies

  • Suppliers and distributors of medical devices

  • Hospitals and diagnostic centers

  • Ambulatory surgery centers

  • Academic centers

  • Venture capitalists



Report Scope:
Report Attribute/Metric Details
  Market Size   79.4 Billion
  CAGR   7.50%
  Base Year   2019
  Forecast Period   2030
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Drug Type, Dosage Form, Basis of System, Therapeutic Applications, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   GlaxoSmithKline Plc. (UK), AstraZeneca (UK), Pfizer, Inc. (US), Becton Dickson & Company (US), Dr. Reddy’s Laboratories Ltd. (India), Sanofi-Aventis (UK), Merck & Co. (US), Cadila Pharmaceuticals (India), AEGIS THERAPEUTICS LLC (US), Novartis AG (UK) , Johnson & Johnson Services, Inc (US) and 3M COMPANY (US)
  Key Market Opportunities   The Increasing number of patient population
  Key Market Drivers   Factors such as the painless drug administration, development of new technological nasal drug delivery devices


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Nasal drug delivery market projected to grow at approximately 7.50% CAGR during the assessment period (2020-2030).

Nasal drug delivery market had valued at around USD 52,998.5 MN in 2018.

Development of new technological nasal drug delivery devices and the increasing number of patient population with respiratory problem, are major tailwinds pushing the growth of the global nasal drug delivery market.

North America holds the largest share in the global nasal drug delivery market, followed by Europe and the Asia Pacific, respectively.

AstraZeneca (UK), 3M COMPANY (US), GlaxoSmithKline Plc. (UK), Novartis AG (UK), Pfizer, Inc. (US), Johnson & Johnson Services, Inc. (US), Dr. Reddy’s Laboratories Ltd. (India), Becton Dickson & Company (US), Sanofi-Aventis (UK), Cadila Pharmaceuticals (India), Merck & Co. (US), and Aegis Therapeutics LLC (US), are some of the top players operating in the global nasal drug delivery market.